Company Performance Metrics
- Mohamed Genead: Co-Founder, CEO & President, Executive Board Director
- Christopher Scott: Scientific Co-FounderPast Role: Queen's University Belfast, Deputy Head of School of Medicine, Dentistry and Biomedical Sciences (Head of Research)
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination of
cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.
Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.
